Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status Confirmatory data to support US regulatory resubmission by year-end; if approved, Dupixent would be the first new targeted treatment for people living with chronic spontaneous urticaria in more than 10 yearsMore than 300,000 people in the US suffe...
Communiqué de presse : Dupixent : Présentation de nouvelles données positives de phase III dans le traitement de l’urticaire chronique spontanée au Congrès de l’ACAAI Dupixent : Présentation de nouvelles données positives de phase III dans le traitement de l’urticaire chronique spontanée au Congrès de l’ACAAI Le Dupixent a permis de réduire significativement le prurit et l’activité de l’urticaire par rapport aux scores à l’inclusion ; un bon niveau de contrôle de la maladie a pu être obtenu chez 41 % des patients. Des données confirmatoires qui seront présentées à l’appui du renouvellem...
NEWS SUMMARY: IBERDROLA, ROVI, VISCOFAN. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 3Q’24 results to be released over the coming days in Spain. IBEX leading the way once again It was a negative session on both sides of the Atlantic, except for the IBEX, in another day with all eyes on results. In the Stoxx 600, most of the sectors (15/20) ended with losses, led by Basic Ma...
>Opinion Neutre et OC à 15.3 € maintenus - Les résultats du 9M 24 sont ressortis un peu au-dessus de nos attentes et de celles du consensus. Comme attendu, la stratégie de résilience du groupe lui permet de bénéficier, sur les trois premiers trimestres, de la progression des activités régulées grâce à la croissance de la base d’actifs et aux révisions tarifaires. Cela a permis de largement compenser une activité de génération bénéficiant certes d’un bon niveau d’hydro...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: IBERDROLA, ROVI, VISCOFAN. EUROPA: DANONE, DEUTSCHE TELEKOM, KERING, SIEMENS. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 3T’24 que se publicarán en España y Europa en los próximos días. El Ibex volvió a liderar Jornada negativa a ambos lados del Atlántico salvo para el Ibex en una nueva sesión descarg...
>Neutral recommendation and € 15.3 target price maintained - Earnings for the first nine months of 2024 came in slightly higher than we and the consensus had forecast. As expected, the group’s strategy to become more resilient allowed it to benefit over the first three quarters from an increase in regulated activities thanks to growth in the asset base and revised tariffs. This handily offset the generation business, which although it benefited from satisfactory hydro...
Last week, we organised an Expert Access event on multiple sclerosis (MS) with the participation of Dr Géraldine Androdias, a neurologist at Lyon University Hospital. Dr Androdias presented the key points of the ECTRIMS 2024 conference, as well as new trends in treating the illness. We note an unmet need in the primary progressive and secondary progressive forms, a real interest for the BTKi class with the greater penetration of the blood-brain barrier, and expectations for the anti-C...
Nous avons organisé la semaine dernière un Expert Access autour de la sclérose en plaques (SEP) avec la participation du Dr Géraldine Androdias, médecin neurologue au CHU de Lyon. Le Dr Androdias a présenté les points saillants du congrès de l’ECTRIMS 2024 ainsi que les nouvelles tendances dans la prise en charge de la maladie. Nous retenons un besoin insatisfait dans les formes progressives et secondairement progressives, un vrai intérêt de la classe des BTKi avec le passage accru de...
>Recurring 9M 2024 results slightly above our expectations and the consensus - The company just disclosed its figures for 9M 2024. Based on recurring (i.e. excluding the € 1.7bn capital gain from Mexico assets disposal), 9M 2024 performance is slightly above our expectations and the market estimates. Recurring EBITDA reached € 11,551m (+11.0%) vs € 10,783m in 9M 2023, recurring EBIT € 7,354m vs € 6,812m in 9M 2023 and recurring net profit € 4,305m (+22.0%) vs € 3,636m...
>Recurring 9M 2024 results slightly above our expectations and the consensus - The company just disclosed its figures for 9M 2024. Based on recurring (i.e. excluding the € 1.7bn capital gain from Mexico assets disposal), 9M 2024 performance is slightly above our expectations and the market estimates. Recurring EBITDA reached € 11,551m (+11.0%) vs € 10,783m in 9M 2023, recurring EBIT € 7,354m vs € 6,812m in 9M 2023 and recurring net profit € 4,305m (+22.0%) vs € 3,636m...
3Q'24 vs. 3Q'23 Results EBITDA: € 3.654 Bn (+13.4% vs. +8.2% BS(e) and +19.4% consensus); Net Profit: € 1.336 Bn (+19.7% vs. +10.3% BS(e) and +1.5% consensus); 9M'24 vs. 9M'23 Results EBITDA: € 11.551 Bn (+7.1% vs. +5.6% BS(e) and +8.9% consensus); Net Profit: € 4.305 Bn (+18.4% vs. +15.5% BS(e) and +12.8% consensus);
Last week, we organised an Expert Access event on multiple sclerosis (MS) with the participation of Dr Géraldine Androdias, a neurologist at Lyon University Hospital. Dr Androdias presented the key points of the ECTRIMS 2024 conference, as well as new trends in treating the illness. We note an unmet need in the primary progressive and secondary progressive forms, a real interest for the BTKi class with the greater penetration of the blood-brain barrier, and expectations for the a...
Nous avons organisé la semaine dernière un Expert Access autour de la sclérose en plaques (SEP) avec la participation du Dr Géraldine Androdias, médecin neurologue au CHU de Lyon. Le Dr Androdias a présenté les points saillants du congrès de l’ECTRIMS 2024 ainsi que les nouvelles tendances dans la prise en charge de la maladie. Nous retenons un besoin insatisfait dans les formes progressives et secondairement progressives, un vrai intérêt de la classe des BTKi avec le passage acc...
Rdos. 3T'24 vs 3T'23: EBITDA: 3.654 M euros (+13,4% vs +8,2% BS(e) y +19,4% consenso); BDI: 1.336 M euros (+19,7% vs +10,3% BS(e) y +1,5% consenso); Rdos. 9meses'24 vs 9meses'23: EBITDA: 11.551 M euros (+7,1% vs +5,6% BS(e) y +8,9% consenso); BDI: 4.305 M euros (+18,4% vs +15,5% BS(e) y +12,8% consenso).
NEWS SUMMARY: ENERGY SECTOR, GLOBAL DOMINION, IBERDROLA. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 3Q’24 results to be released over the coming days in Spain. Debt cools the markets European stock markets ended flat in a session marked by the doubts surrounding the sustainability of sovereign debt. In the STOXX 600, Technology led the gains, with Utilities and Insurance p...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: GLOBAL DOMINION, IBERDROLA, SECTOR ENERGÉTICO. EUROPA: AIR LIQUIDE, L’ORÉAL. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 3T’24 que se publicarán en España y Europa en los próximos días. La deuda enfría los mercados De menos a más, las bolsas europeas terminaron planas en una jornada marcada por las duda...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.